Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
Bluebird bio news centers on the company's commercial-stage gene therapy business for severe genetic diseases and its completed acquisition by funds managed by Carlyle and SK Capital. The company developed and delivered FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, with recurring updates tied to commercial delivery, manufacturing infrastructure, treatment-center support, payer partnerships, and patient access.
Company news also documents the transaction process that ended Bluebird bio's public listing, including tender-offer communications, merger-agreement amendments, capital-structure matters, governance actions, and the cessation of trading in its common stock after the acquisition closed.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
bluebird bio announced the submission of its Biologics License Application (BLA) to the FDA for lovotibeglogene autotemcel (lovo-cel) gene therapy aimed at treating sickle cell disease (SCD) in patients aged 12 and older. This submission is based on extensive clinical data, including results from 36 patients with a median follow-up of 32 months. The company is seeking Priority Review to potentially expedite the FDA's decision to six months. If approved, lovo-cel would become bluebird bio's third gene therapy for a rare genetic disorder. The FDA has previously granted several designations for lovo-cel, recognizing its potential impact on a significant patient population affected by SCD, a serious condition impacting 100,000 people in the U.S.